Histology-Driven Chemotherapy in Soft Tissue Sarcomas
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Oncology
Link
http://link.springer.com/content/pdf/10.1007/s11864-011-0140-x.pdf
Reference46 articles.
1. Sleijfer S, Seynaeve C, Verweij J. Using single agent therapy in adult patients with advanced soft tissue sarcomas can still be considered standard. Oncologist 2005, 10: 833–841.
2. Judson I, Radford J, Harris M, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2001; 37: 870–877
3. Van Glabbeke M, Van Oosterom AT, Oosterhuis JW, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: An analysis of 2185 patients treated with anthracycline-containing first-line regimens—a European Organization for the Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 1999, 17: 150–157.
4. Tascilar M, Loos WJ, Seynaeve C, et al. The pharmacological basis of ifosfamide use in adult patients with advanced soft tissue sarcomas. The Oncologist 2007, 12: 1351–1360
5. Sleijfer S, Ouali M, van Glabbeke M, et al. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer 2010;46:72–83.
Cited by 38 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Therapeutic advances in leiomyosarcoma;Frontiers in Oncology;2023-03-08
2. Clinical outcomes of brain metastasectomy from soft tissue and bone sarcomas: a systematic review;International Journal of Clinical Oncology;2022-08-22
3. Combination of ifosfamide and etoposide as a salvage regimen for previously treated soft tissue sarcomas: a retrospective single centre study;ecancermedicalscience;2022-03-03
4. Personalised pharmacotherapy options for soft tissue sarcomas;Expert Review of Precision Medicine and Drug Development;2022-01-02
5. Maximizing Immunotherapy in Sarcoma Using Histology, Biomarkers and Novel Approaches;Oncology & Haematology;2022
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3